The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGeiger Counter Regulatory News (GCL)

Share Price Information for Geiger Counter (GCL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 52.70
Bid: 52.40
Ask: 53.00
Change: 0.70 (1.35%)
Spread: 0.60 (1.145%)
Open: 52.50
High: 52.70
Low: 52.50
Prev. Close: 52.00
GCL Live PriceLast checked at -
Geiger Counter is an Investment Trust

To deliver attractive returns to shareholders principally in the form of capital growth, through investment in companies involved in the exploration, development and production of uranium to supply the nuclear power industry.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Results of Subscription Rights Exercise

5 May 2022 09:30

RNS Number : 4397K
Geiger Counter Ltd
05 May 2022
 

 

5 May 2022

GEIGER COUNTER LIMITED(THE "COMPANY")

 

Result of subscription rights exercise for Ordinary Shares

The Board of the Company is pleased to announce that applications have been received from shareholders to subscribe for 17,376,023 new ordinary shares of no par value ("Ordinary Shares") at a price of 37.84p per share. As previously announced, as there is a cap of Euro 8 million on the value of Ordinary Shares that can be issued at the subscription price, each successful applicant has had the number of shares they have applied for scaled back to approximately 76.67 per cent of the number applied for. A total of 13,322,132 Ordinary Shares will therefore be issued to the successful applicants on the basis of one new Ordinary Share for every five existing Ordinary Shares registered in the name of the successful applicants on the record date, 6pm 3 May 2022.

Outstanding Subscription Rights

Shareholders holding approximately 23.33% of the Company's issued share capital did not apply to take up their subscription rights entitlement, representing a total of 4,474,044 Ordinary Shares. In accordance with the terms and conditions on which the Subscription Rights were issued, the Company has appointed a trustee (the "Subscription Trustee"). If the Subscription Trustee is of the opinion, having consulted finnCap Limited ("finnCap"), that the net proceeds of sale of the Ordinary Shares arising on exercise of the outstanding Subscription Rights (after deduction of all costs and expenses incurred by, and any fee due to, the Subscription Trustee) will exceed the aggregate costs of subscription, the Subscription Trustee will exercise either (i) all the Subscription Rights which have not been exercised or (ii) at the Subscription Trustee's discretion such number of Subscription Rights as will, in the Subscription Trustee's opinion, result in the Ordinary Shares arising from such exercise being sold in the market for such net proceeds as will exceed the costs of exercising such Subscription Share Rights and the costs and expenses of sale.

It is intended that the full number of Ordinary Shares that would arise from the exercise of the outstanding Subscription Rights (the "Rump") will be sold by finnCap by way of a secondary market placing executed at the maximum available, single clearing price. However, the Subscription Trustee reserves its absolute discretion to execute bargains in such sizes and prices as it deems appropriate to the interests of the outstanding Subscription Shareholders. Qualified investors (as defined in section 86(7) of the Financial Services and Markets Act 2000 (as amended)) considering participation in the secondary market placing are advised to contact finnCap as soon as practicable. Orders for the placing should state the number of shares to be purchased and the maximum purchase price (or confirm that the investor is willing to trade "at strike"). Investors placing orders should note that if the full extent of the Rump is not covered, then a bargain is expected to be executed at the maximum available, single clearing price for the actual size of the book.

If the Subscription Trustee is of the opinion that the gross proceeds of sale of the Ordinary Shares by the Subscription Trustee are likely to exceed the costs of subscription but the excess is not sufficient to meet the costs and expenses incurred by the Subscription Trustee, the Board intends that part or all of such costs and expenses will be borne by the Company, provided that at that time the Board believes this to be in the best interests of the Company and Shareholders as a whole.

The Subscription Trustee will distribute the proceeds of any sale (less any related subscription costs and other costs and expenses) pro rata to the persons entitled thereto, provided that entitlements of under £5.00 shall be retained for the benefit of the Company.

Accordingly, the Company announces that it will be issuing and allotting 13,322,132 Ordinary Shares, subject to admission to trading. Application will be made for the new Ordinary Shares to be admitted to trading on The International Stock Exchange ("TISE") and to trading on the London Stock Exchange's SETSqx platform. It is expected that dealings will commence at 8.00 a.m. on 10 May 2022.

Total Voting Rights

For the purposes of the Financial Conduct Authority's Disclosure Guidance and Transparency Rules ("DTRs"), following Admission the issued ordinary share capital of the Company will consist of 129,379,109 Ordinary Shares with voting rights attached. The Company does not hold any shares in treasury. This figure of 129,379,109 may be used by the Company's shareholders as the denominator for the calculation by which they will determine whether they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the DTRs.

As outlined in the circular sent to Shareholders relating to the subscription rights, all shareholders will have a further right to subscribe for shares on 2 May 2023 (on the basis of one new Ordinary Share for every five Ordinary Shares held). The subscription price will be equal to the unaudited diluted net asset value per share on 4 May 2022. A reminder will be sent to shareholders prior to the next subscription date.

The information contained within this RNS is considered to be inside information prior to its release.

For further information, please contact:

CQS (UK) LLP

Craig Cleland

 

+44 (0) 20 7201 5368

finnCap Limited

William Marle / Milesh Hindocha - Corporate Finance

 

+44 (0) 20 7220 0500

Mark Whitfeld / Pauline Tribe - Sales

+44 (0) 20 7220 0500

R&H Fund Services (Jersey) Limited

Jane De Barros-Sousa

+44 (0) 1534 825 259

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCMZGGKRKKGZZG
Date   Source Headline
20th Feb 20241:55 pmRNSNet Asset Value(s)
20th Feb 202412:00 pmRNSShare Buyback
19th Feb 20243:00 pmRNSNet Asset Value(s)
19th Feb 202411:00 amRNSShare Buyback
16th Feb 20241:30 pmRNSNet Asset Value(s)
16th Feb 202412:00 pmRNSShare Buyback
15th Feb 202412:35 pmRNSNet Asset Value(s)
15th Feb 202411:00 amRNSShare Buyback
14th Feb 20242:05 pmRNSNet Asset Value(s)
14th Feb 20241:30 pmRNSShare Buyback
13th Feb 20241:25 pmRNSNet Asset Value(s)
13th Feb 202410:30 amRNSShare Buyback
9th Feb 20241:45 pmRNSNet Asset Value(s)
8th Feb 20243:30 pmRNSPotential listing on the London Stock Exchange
8th Feb 20243:05 pmRNSNet Asset Value(s)
7th Feb 20242:00 pmRNSNet Asset Value(s)
6th Feb 20242:15 pmRNSNet Asset Value(s)
5th Feb 20242:45 pmRNSNet Asset Value(s)
2nd Feb 20243:55 pmRNSNet Asset Value(s)
1st Feb 20243:45 pmRNSNet Asset Value(s)
31st Jan 202412:20 pmRNSNet Asset Value(s)
30th Jan 20242:00 pmRNSNet Asset Value(s)
29th Jan 20243:05 pmRNSNet Asset Value(s)
26th Jan 202412:25 pmRNSNet Asset Value(s)
25th Jan 202412:45 pmRNSNet Asset Value(s)
24th Jan 202412:50 pmRNSNet Asset Value(s)
24th Jan 202410:15 amRNSMonthly factsheet December 2023
23rd Jan 20244:25 pmRNSNet Asset Value(s)
22nd Jan 20243:45 pmRNSNet Asset Value(s)
19th Jan 20241:15 pmRNSNet Asset Value(s)
18th Jan 20241:45 pmRNSNet Asset Value(s)
17th Jan 20241:05 pmRNSNet Asset Value(s)
16th Jan 202412:30 pmRNSNet Asset Value(s)
15th Jan 20241:10 pmRNSNet Asset Value(s)
12th Jan 202412:45 pmRNSNet Asset Value(s)
11th Jan 20241:45 pmRNSNet Asset Value(s)
10th Jan 20241:45 pmRNSNet Asset Value(s)
9th Jan 20242:00 pmRNSNet Asset Value(s)
8th Jan 20243:30 pmRNSNet Asset Value(s)
5th Jan 20244:00 pmRNSNet Asset Value(s)
4th Jan 20243:05 pmRNSNet Asset Value(s)
3rd Jan 20243:20 pmRNSNet Asset Value(s)
29th Dec 20231:30 pmRNSNet Asset Value(s)
28th Dec 20233:20 pmRNSNet Asset Value(s)
27th Dec 20234:00 pmRNSNet Asset Value(s)
27th Dec 20234:00 pmRNSAnnual Financial Report - 30 September 2023
27th Dec 202311:15 amRNSMonthly Factsheet: November 2023
22nd Dec 202312:40 pmRNSNet Asset Value(s)
21st Dec 20233:50 pmRNSNet Asset Value(s)
20th Dec 20233:50 pmRNSNet Asset Value(s)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.